Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?

Immunotherapy

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

Front Immunol.

Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S

doi: 10.3389/fimmu.2019.01613.

Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma

Curr Res Transl Med.

Ghobadi A

doi: 10.1016/

T CellsImmune Response

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

J Clin Oncol

Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M

doi: 10.1200/JCO.21.01992

T Cells

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Lancet

Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W, UCART19 Group.

doi: 10.1016/S0140-6736(20)32334-5

Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared to CD3-targeted T-cell depletion

Transpl Infect Dis.

Triplett BM, Muller B, Kang G, Ying L, Cross SJ, Moen J, Cunningham L, Janssen W, Mamcarz E, Shook DR, Srinivasan A, Choi J, Hayden RT, Leung W

doi: 10.1111/tid.12823.

Immunotherapy

CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases

Front Immunol.

Seif M, Einsele H, Löffler J

doi: 10.3389/fimmu.2019.02711.

Immunotherapy

Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy

Clin Cancer Res

Huarte E, O'Conner RS, Peel MT, Nunez-Cruz S, Leferovich J, Juvekar A, Yang YO, Truong L, Huang T, Naim A, Milone MC, Smith PA

doi: 10.1158/1078-0432.CCR-20-1739

ImmunotherapyT Cells

Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV-specific T cell therapy

Clin Exp Immunol

Cooper RS, Kowalczuk A, Wilkie G, Vickers MA, Turner ML, Campbell JDM, Fraser AR

doi: 10.1111/cei.13640

ImmunotherapyT Cells

Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology

Front Immunol.

Mylvaganam G, Yanez AG, Maus M, Walker BD

doi: 10.3389/fimmu.2019.02109.

Related content

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared to CD3-targeted T-cell depletion

CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases

Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy

Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV-specific T cell therapy

Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology